Immatics (IMTX) Projected to Post Earnings on Wednesday

Immatics (NASDAQ:IMTX) is expected to post its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect Immatics to post earnings of ($0.43) per share and revenue of $11.9030 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 13, 2026 at 12:30 PM ET.

Immatics (NASDAQ:IMTX) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.08). Immatics had a negative net margin of 572.35% and a negative return on equity of 47.36%. The firm had revenue of $8.81 million during the quarter, compared to analysts’ expectations of $9.79 million. On average, analysts expect Immatics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Immatics Stock Performance

Shares of NASDAQ IMTX opened at $9.38 on Wednesday. Immatics has a 1 year low of $5.05 and a 1 year high of $12.41. The firm has a market cap of $1.26 billion, a price-to-earnings ratio of -4.71 and a beta of 1.33. The stock’s 50-day simple moving average is $9.66 and its 200-day simple moving average is $10.08.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on IMTX shares. Wall Street Zen downgraded Immatics from a “hold” rating to a “sell” rating in a report on Saturday, May 2nd. TD Cowen assumed coverage on Immatics in a research note on Tuesday, April 28th. They set a “buy” rating for the company. Weiss Ratings downgraded shares of Immatics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, June 23rd. Finally, Chardan Capital restated a “buy” rating and issued a $25.00 price target on shares of Immatics in a research note on Tuesday, May 19th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Immatics currently has a consensus rating of “Moderate Buy” and an average price target of $20.80.

Institutional Trading of Immatics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of America Corp DE raised its stake in Immatics by 166.0% during the fourth quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock valued at $25,000 after buying an additional 2,231 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of Immatics by 31.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 198,769 shares of the company’s stock worth $1,069,000 after acquiring an additional 47,590 shares in the last quarter. BNP Paribas Financial Markets grew its position in shares of Immatics by 105.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 78,123 shares of the company’s stock worth $420,000 after acquiring an additional 40,058 shares in the last quarter. Engineers Gate Manager LP bought a new stake in shares of Immatics in the 2nd quarter valued at approximately $124,000. Finally, Sofinnova Investments Inc. increased its holdings in shares of Immatics by 44.1% in the 2nd quarter. Sofinnova Investments Inc. now owns 2,240,528 shares of the company’s stock valued at $12,054,000 after acquiring an additional 686,224 shares during the last quarter. 64.41% of the stock is owned by institutional investors.

About Immatics

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.